X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1577) 1577
Publication (163) 163
Book Review (27) 27
Book Chapter (7) 7
Conference Proceeding (3) 3
Data Set (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1151) 1151
humans (1101) 1101
sofosbuvir (1040) 1040
hepatitis c (898) 898
hepatitis c virus (791) 791
antiviral agents - therapeutic use (736) 736
ribavirin (710) 710
hepatitis c, chronic - drug therapy (706) 706
male (662) 662
gastroenterology & hepatology (627) 627
female (618) 618
middle aged (609) 609
hepatitis (542) 542
interferon (528) 528
drug therapy, combination (503) 503
treatment outcome (474) 474
hepacivirus - genetics (473) 473
genotype (445) 445
antiviral agents - adverse effects (417) 417
aged (394) 394
adult (386) 386
cirrhosis (375) 375
antiviral agents (371) 371
ledipasvir (345) 345
health aspects (337) 337
hcv (332) 332
virus-infection (325) 325
antiviral agents - administration & dosage (323) 323
hepatitis c - drug therapy (309) 309
hepacivirus - drug effects (308) 308
ribavirin - therapeutic use (300) 300
liver (299) 299
therapy (295) 295
sofosbuvir - therapeutic use (291) 291
infection (287) 287
patients (283) 283
care and treatment (280) 280
pharmacology & pharmacy (275) 275
drug therapy (268) 268
infections (263) 263
liver cirrhosis (263) 263
hepatitis c, chronic - virology (259) 259
sustained virological response (246) 246
analysis (220) 220
genotype 1 infection (219) 219
genotype & phenotype (217) 217
sustained virologic response (215) 215
biological response modifiers (212) 212
daclatasvir (211) 211
infectious diseases (209) 209
treatment-naive patients (208) 208
sofosbuvir - adverse effects (194) 194
genotype 1 (187) 187
uridine monophosphate - analogs & derivatives (187) 187
simeprevir (183) 183
transplantation (181) 181
direct-acting antivirals (172) 172
sofosbuvir - administration & dosage (172) 172
genotypes (170) 170
hepatitis c, chronic - complications (170) 170
genetic aspects (167) 167
viruses (163) 163
liver transplantation (159) 159
pegylated interferon (158) 158
virus diseases (155) 155
gastroenterology and hepatology (154) 154
hepatology (154) 154
efficacy (149) 149
plus ribavirin (147) 147
retrospective studies (147) 147
ribavirin - administration & dosage (147) 147
treatment-naive (147) 147
medical research (142) 142
open-label (141) 141
safety (137) 137
ribavirin - adverse effects (135) 135
young adult (135) 135
antiviral therapy (133) 133
uridine monophosphate - therapeutic use (131) 131
liver diseases (129) 129
telaprevir (128) 128
virology (128) 128
abridged index medicus (126) 126
hcv infection (125) 125
hepatitis-c virus (125) 125
combination (124) 124
medicine, experimental (124) 124
viral load (124) 124
sofosbuvir plus ribavirin (122) 122
liver cirrhosis - virology (121) 121
benzimidazoles - therapeutic use (120) 120
recurrence (120) 120
medicine, general & internal (117) 117
medicine & public health (116) 116
chronic infection (115) 115
fluorenes - therapeutic use (115) 115
clinical trials (114) 114
research (114) 114
hepatitis c - virology (111) 111
risk factors (108) 108
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1558) 1558
Korean (7) 7
German (6) 6
Spanish (5) 5
Chinese (2) 2
French (1) 1
Hungarian (1) 1
Italian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


ALIMENTARY PHARMACOLOGY & THERAPEUTICS, ISSN 0269-2813, 05/2018, Volume 47, Issue 9, pp. 1296 - 1305
BackgroundInterferon-free regimens are associated with high sustained virological response; however, associated adverse effects have yet to be fully reported.... 
GENOTYPE 4 INFECTION | SHORT-TERM RISK | HEPATOCELLULAR-CARCINOMA | VIRUS-INFECTION | TREATMENT-NAIVE | SOFOSBUVIR PLUS RIBAVIRIN | DIRECT-ACTING ANTIVIRALS | SIMEPREVIR | PHARMACOLOGY & PHARMACY | OPEN-LABEL | HCV | GASTROENTEROLOGY & HEPATOLOGY
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 07/2017, Volume 57, Issue 7, pp. 931 - 932
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2014, Volume 370, Issue 17, pp. 1594 - 1603
In this trial in previously untreated patients with HCV genotype 1 infection and no cirrhosis, high rates of sustained response were achieved with three new... 
TRIAL | MEDICINE, GENERAL & INTERNAL | PLUS SOFOSBUVIR | C VIRUS-INFECTION | GENOTYPE 1 INFECTION | DACLATASVIR | SIMEPREVIR TMC435 | HEPATITIS-C | INTERFERON-FREE | TREATMENT-NAIVE PATIENTS | PHASE 2B | Anilides - therapeutic use | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Viral Load | Young Adult | Ritonavir - adverse effects | Ritonavir - therapeutic use | Adult | Female | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Uracil - therapeutic use | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Adolescent | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Drug Combinations | Uracil - analogs & derivatives | Dosage and administration | Research | Drug therapy, Combination | Hepatitis C | Drug therapy | Ribavirin | Ritonavir | Body weight | Diarrhea | Infections | Nausea | Proteinase inhibitors | Pruritus | Drug resistance | Patients | Genotype & phenotype | Cirrhosis | Sleep disorders | Hepatitis | Asthenia | Hemoglobin | Interferon | Drug dosages | Genotypes
Journal Article
European Journal of Gastroenterology & Hepatology, ISSN 0954-691X, 10/2018, Volume 30, Issue 10, pp. 1177 - 1186
OBJECTIVENew potent direct-acting antiviral (DAA) regimens against hepatitis C virus have been approved in recent years. However, information about the rate of... 
ribavirin | ledipasvir and sofosbuvir | hepatitis C virus | ombitasvir and dasabuvir | genotype 1 | adverse events | randomized | direct-acting antivirals | paritaprevir | ACUTE LIVER-FAILURE | VIRUS-INFECTION | SOFOSBUVIR | HCV INFECTION | REAL-WORLD EFFECTIVENESS | SUSTAINED VIROLOGICAL RESPONSE | DASABUVIR | GENOTYPE 1B CIRRHOSIS | RITONAVIR-BOOSTED PARITAPREVIR | GASTROENTEROLOGY & HEPATOLOGY | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Fatigue - chemically induced | Drug Therapy, Combination - adverse effects | Ritonavir - adverse effects | Adult | Female | Fluorenes - adverse effects | Sofosbuvir - adverse effects | Benzimidazoles - adverse effects | Headache - chemically induced | Antiviral Agents - therapeutic use | Anemia - chemically induced | Genotype | Treatment Outcome | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Uracil - adverse effects | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Viral Load - drug effects | Uracil - analogs & derivatives | Drugs | Antiviral agents | Complications and side effects | Treatment outcome | Usage | Analysis | Adverse and side effects | Hepatitis C | Drug therapy | Risk factors
Journal Article
Gastroenterology, ISSN 0016-5085, 2014, Volume 147, Issue 2, pp. 359 - 365.e1
Background & Aims The interferon-free regimen of ABT-450 (a protease inhibitor), ritonavir, ombitasvir (an NS5A inhibitor), dasabuvir (a non-nucleoside... 
Gastroenterology and Hepatology | IFN | PEARL-II | Ribavirin-Free | Interferon-Free Therapy | PLUS RIBAVIRIN | ABT-450/R-OMBITASVIR | VIRUS-INFECTION | TELAPREVIR | SOFOSBUVIR | CHRONIC HEPATITIS-C | COMBINATION | TRIAL | CIRRHOSIS | BOCEPREVIR | GASTROENTEROLOGY & HEPATOLOGY | Anilides - therapeutic use | Puerto Rico | Hepatitis C - drug therapy | United States | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Male | RNA, Viral - blood | Viral Load | Ritonavir - adverse effects | Time Factors | Ritonavir - therapeutic use | Adult | Female | Drug Therapy, Combination | Hepacivirus - drug effects | Antiviral Agents - therapeutic use | Europe | Ribavirin - therapeutic use | Uracil - therapeutic use | Genotype | Treatment Outcome | Macrocyclic Compounds - adverse effects | Biomarkers - blood | Macrocyclic Compounds - therapeutic use | Hepatitis C - diagnosis | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Hepacivirus - growth & development | Aged | Carbamates - therapeutic use | Uracil - analogs & derivatives | Medical colleges | Care and treatment | Proteases | Ritonavir | Biological products industry | Genetic aspects | Biological response modifiers | Hepatitis C virus | Hepatitis C | Health aspects | Ribavirin
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2017, Volume 376, Issue 22, pp. 2134 - 2146
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2013, Volume 368, Issue 20, pp. 1878 - 1887
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2015, Volume 15, Issue 6, pp. 645 - 653
Summary Background Compared with other countries, patients with chronic hepatitis C infection in Japan tend to be older, have more advanced liver disease, and... 
Infectious Disease | INFECTIOUS DISEASES | SIMEPREVIR | INFECTION | CHRONIC HCV | Uridine Monophosphate - administration & dosage | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Drug-Related Side Effects and Adverse Reactions - pathology | Young Adult | Benzimidazoles - administration & dosage | Time Factors | Ribavirin - administration & dosage | Aged, 80 and over | Adult | Female | Fluorenes - administration & dosage | Fluorenes - adverse effects | Uridine Monophosphate - adverse effects | Benzimidazoles - adverse effects | Hepacivirus - isolation & purification | Administration, Oral | Japan | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Drug-Related Side Effects and Adverse Reactions - epidemiology | Asian Continental Ancestry Group | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Aged | Hepacivirus - classification | Sofosbuvir | Care and treatment | Liver | Dosage and administration | Product development | Drug therapy, Combination | Hepatitis C virus | Hepatitis C | Health aspects | Ribavirin | Hepatitis | Genotype & phenotype | Liver cancer | Heart attacks | Liver diseases | Human immunodeficiency virus--HIV | Hepatology | Response rates | Interferon | Infections | Drug dosages | Patients
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 20, pp. 1879 - 1888
Journal Article